ERBB2 and breast carcinoma: Substantial, randomized, and controlled studies of HER2‐targeted therapies have been advantageous for patients with HER2‐positive gastroesophageal adenocarcinoma and breast cancer, as HER2 overexpression and amplification is more frequent in these cancers.